Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present CohBar Inc. (NASDAQ: CWBR).

Full DD Report for CWBR

You must become a subscriber to view this report.


Recent News from (NASDAQ: CWBR)

Microcaps mostly among midday movers
More news on: Datawatch Corporation, JinkoSolar Holding Co., Ltd., Yulong Eco-Materials, , Stocks on the move, Read more ...
Source: SeekingAlpha
Date: November, 05 2018 12:46
CohBar down 39% on suspension of early-stage study of lead NASH candidate
Thinly traded micro cap CohBar ( CWBR -39% ) slumps on more than double normal volume, albeit on turnover of only 229K shares, in reaction to the suspension of a Phase 1 clinical trial evaluating NASH and obesity candidate CB4211. The company took action in order to address mild injectio...
Source: SeekingAlpha
Date: November, 05 2018 10:27
CohBar Provides Update on CB4211 Clinical Trial
CB4211 Phase 1 Clinical Trial Temporarily Suspended to Address Injection Site Reactions Will Host Conference Call on November 6, 2018 at 11:00 a.m. Eastern Time MENLO PARK, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company...
Source: GlobeNewswire
Date: November, 05 2018 09:00
CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018
MENLO PARK, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it will release its third quarter 2018 financial results after the ...
Source: GlobeNewswire
Date: October, 31 2018 09:00
CohBar Inc. (CWBR) CEO Simon Allen on Q2 2018 Results - Earnings Call Transcript
CohBar Inc. (CWBR) Q2 2018 Results Earnings Conference Call August 14, 2018, 05:00 PM ET Executives Jeff Biunno - CFO Simon Allen - CEO Kenneth Cundy - Chief Scientific Officer Analysts Ed Arce - H.C. Wainwright & Company Clay Chase - Torrey Hills Capital Presentat...
Source: SeekingAlpha
Date: August, 14 2018 19:52
CohBar beats by $0.07
CohBar (NASDAQ: CWBR ): Q2 EPS of -$0.08 beats by $0.07 . More news on: CohBar Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 14 2018 16:18
CohBar Announces Second Quarter 2018 Financial Results
MENLO PARK, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today reported financial results for the second quarter ended June 30, 2018. “...
Source: GlobeNewswire
Date: August, 14 2018 16:03
Technology - Top 5 Gainers / Losers as of 3.05 PM (08/07/2018)
Gainers:  IFMK +51% . CWBR +35% . EKSO +30% . FIVN +25% . ONDK +24% . More news on: iFresh Inc., CohBar Inc., Ekso Bionics Holdings, Inc., Tech stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: August, 07 2018 15:07
Midday Gainers / Losers (08/07/2018)
Gainers: IFMK +70% . VCEL +26% . ONDK +25% . EKSO +25% . CVGI +24% . HTZ +24% . MNK +24% . CWBR +24% . TIS +23% . FIVN +22% . More news on: iFresh Inc., Vericel Corporation, OnDeck Capital, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 07 2018 12:40
CohBar, Inc. to Announce 2018 Second Quarter Financial Results and Host Conference Call for Shareholders on August 14, 2018
MENLO PARK, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the company will release its second quarter 2018 financial res...
Source: GlobeNewswire
Date: August, 02 2018 13:09

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-084.904.764.924.7076,117
2018-05-185.985.905.985.804927,416
2018-05-175.985.905.985.804927,416

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-131,8734,02546.5342Short
2018-12-122,4975,36946.5077Short
2018-12-117834,68416.7165Cover
2018-12-101,9925,64535.2879Short
2018-12-071,5003,10648.2936Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CWBR.


About CohBar Inc. (NASDAQ: CWBR)

Logo for CohBar Inc. (NASDAQ: CWBR)

CohBar, Inc. OTCQX: CWBR and TSXV: COB.U is an innovative biotechnology company focused on the research and development of mitochondria based therapeutics MBTs , an emerging class of drugs for the treatment of age related diseases. MBTs originate from the discovery by CohBar s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar s efforts focus on the development of these mitochondrial derived peptides MDPs into clinically relevant MBTs that offer the potential to address a broad range of age related diseases, including NASH, obesity, type diabetes, cancer, cardiovascular and neurodegenerative diseases. To date, the Company and its founders have discovered more than MDPs.

 

Contact Information

 

 

Current Management

  • Simon J. Allen / CEO
  • Jon L. Stern / COO
  • Jeffrey F. Biunno / CFO, Secretary, Treasurer
  • Kenneth Cundy / CSO
  • Abion J. Fitzgerald / Chairman, Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • John Amatruda /
  • Nir Barzilai / Audit Committee Member
  • Pinchas Cohen / Nominating Committee Member
  • Marc E. Goldberg / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Jon L. Stern /

Current Share Structure

  • Market Cap: $206,181,438 - 03/15/2018
  • Authorized: 75,000,000 - 01/05/2015
  • Issue and Outstanding: 39,422,837 - 11/15/2017
  • Float: 24,134,745 - 09/30/2017

 


Recent Filings from (NASDAQ: CWBR)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 11 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: May, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 04 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: May, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 04 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: May, 04 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018

 

 


Daily Technical Chart for (NASDAQ: CWBR)

Daily Technical Chart for (NASDAQ: CWBR)


Stay tuned for daily updates and more on (NASDAQ: CWBR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CWBR)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CWBR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CWBR and does not buy, sell, or trade any shares of CWBR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/